Novartis’s Zolgensma comes out on top versus Biogen’s Spinraza, but neither is deemed cost effective by Icer.
Pfizer and Merck & Co take increases, making it easier for others to follow. But shifts in congressional power means pricing will remain a minefield.
Split congressional control will result in more drug pricing talk, but don’t expect much action.
Novartis's $4m price target for AVXS-101 fuels concerns that too many new gene therapies could overburden payers without a hard look at how they are financed.
The price isn’t the real price, even in overseas markets. And if the US government is serious about drug price reductions, should it return to the idea of direct…
Repatha's price reduction could say more about the state of US politics and competition than it does about long term cost-lowering.
Disclosing prices to consumers looks like a fait accompli, although the details are still being debated. Icer, meanwhile, could open the door to biopharma’s early…
Big pharma’s freezes have stopped drug price inflation in its tracks, but the temptation to make more hikes could return post-election.
As Anaptysbio pushes forward with its new biological, the cost watchdog Icer questions the prices of products from Glaxosmithkline, Astrazeneca and Teva.